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Abstract
Anal cancer is uncommon neoplasm with an incidence of 2 new cases per 100,000 per year in the USA, accounting
approximately 0.4 % of all tumors and 2.5 % of gastrointestinal malignancies. An early detection of the anal cancer
is crucial for the patient management, whereas the diagnosis at an early stage allows conservative management
with sphincter sparing, on the contrary a delays in diagnosis might lead to an advance cancer stage at presentation
with worst survival. According to National Comprehensive Cancer Network (NCCN) Anal Carcinoma guidelines the
patients should be subjected to a careful clinical examination, including a digital rectal examination (DRE), an
anoscopic examination, and palpation of inguinal nodes. The guidelines recommended for the assessment of T
stage, only a clinical examination, while the role of imaging techniques, as Magnetic Resonance imaging (MRI) is
limited to the identification of regional nodes. Instead, the endoanal ultrasound (EAUS) is not recommended. This
paper presents an overview and some updates about 3D EAUS and MRI in detection, staging and assessment post
therapy of anal cancer patients.
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Background
Anal caner is uncommon neoplasm with an incidence of 2
new cases per 100,000 per year in the USA [1], accounting
approximately 0.4 % of all tumors and 2.5 % of gastrointes-
tinal malignancies [2, 3]. Compared to 30 years ago, the in-
cidence increased by about 2 fold higher (1.9 fold for men
and 1.5 for women) [3]. Several risk factors have been
identified: the number of sexual partners, cigarette smok-
ing, genital warts, a history of vulvar, vaginal or cervical
cancer, immunosuppression after solid transplantation,
hematologic malignancies and viral infections by hu-
man papillomavirus (HPV), and human immunodeficiency
virus (HIV) [3–6]. Some studies showed that the increasing
incidence of anal carcinoma might reflect an increase in in-
fection rates of HPV and HIV [5–10].
Most primary cancers of the anus are squamous cell car-
cinomas [11]. Lymphatic drainage of tumor is dependent
on location of the lesion in the anal region [11]: cancer in
the perianal skin and in distal anal canal drains to superfi-
cial nodes, while tumors in the proximal anal canal drain
in anorectal, perirectal, paravertebral nodes and also in in-
ternal iliac nodes (Fig. 1) [11]. Diagnosis based only on pa-
tient’s clinical history is complicated since anal tumor is
characterized by a considerable overlap of symptoms with
benign diseases: 45 % of patients report rectal bleeding,
20–35 % anorectal pain and 20–35 % sensation of a rectal
mass [7, 8]. An early detection of the anal cancer is crucial
for the patient management, whereas the diagnosis at an
early stage allows conservative management with sphincter
sparing. [9, 12, 13] On the contrary, a delays in diagnosis
might lead to an advance cancer stage at presentation with
worst survival, [8]. The recent improvements of neoadju-
vant therapies, radiotherapy and chemotherapy, can also
down staging the lesion, as well as to allow a conservative
treatment [9–14]. According to National Comprehensive
Cancer Network (NCCN) Anal Carcinoma Guidelines the
patients should be subjected to a careful clinical examin-
ation, including a digital rectal examination (DRE), an ano-
scopic examination, and palpation of inguinal nodes [15].
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The NCCN recommended for the assessment of T stage
(Table 1) only a clinical examination, while the role of im-
aging techniques, as Magnetic Resonance imaging (MRI)
is limited to the identification of regional nodes. The
endoanal ultrasound (EAUS) is not recommended [15].
However, the clinical examination alone does not allow to
evaluate the relationship of the tumor with structures such
as sphincter plan, vagina, cervix, urethra, which is obliga-
tory to confirm the stage of the cancer and to choose
therapeutic strategy, since tumors in stage T2 and T3/T4
(Table 2) are usually treated surgically or with neoadjuvant
therapy, respectively [13]. Also, NCCN guidelines recom-
mend that the surveillance post primary treatment of non
metastatic cancer should be by DRE between 8–12 weeks
after neoadjuvant therapy and these patients should
undergo evaluation every 3 – 6 months for 5 years by
DRE, anoscopic evaluation and inguinal node palpation.
For patients with slow disease regression is recommended
an annual chest, abdominal and pelvic imaging [15].
Fig. 1 Anatomical scheme of anal canal: levator ani, longitudinal muscle o rectum, anorectal junction, dentate line, anal verge, anal margin,
internal sphincter and external sphincter
Table 1 TNM Classification for anal cancer
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ (Bowen disease, high-grade squamous
intraepithelial lesion [HSIL], anal intraepithelial neoplasia
II-III (AIN II-III)
T1 Tumor 2 cm or less in greatest dimension
T2 Tumor more than 2 cm but not more than 5 cm in greatest
dimension
T3 Tumor more than 5 cm in greatest dimension
T4 Tumor of any size invades adjacent organ(s) (eg, vagina,
urethra, bladder);direct invasion of the rectal wall, perirectal
skin, subcutaneous tissue, or the sphincter muscle(s) is not
classified as T4
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in perirectal lymph node(s)
N2 Metastasis in unilateral internal iliac and/or inguinal lymph node(s)
N3 Metastasis in perirectal and inguinal lymph nodes and/or
bilateral internal iliac and/or inguinal lymph nodes
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Table 2 Anatomic stage
Stage T N M
0 Tis N0 M0
I T1 N0 M0
II T2 N0 M0
T3 N0 M0




IIIB T4 N1 M0
Any T N2 M0
Any T N3 M0
IV Any T Any N M1
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Both the 3-dimensional (3D) EAUS and MRI allows to
perform a detailed evaluation of the multilayer wall of the
anus, to detect the lesion, to stage the lesion, to identify
the relations with adjacent structures and the presence of
lymphadenopathy [16].
This paper reports an overview and some updates
about 3D EAUS and MRI in detection, staging and as-
sessment post therapy in anal cancer patients.
Materials and methods
Data for this review were identified by searches of the
PubMed database using a multimodal strategy. The fol-
lowing search terms were employed: endo sonography in
anal cancer, three Dimensional-Endoanal-sonography in
anal cancer, Magnetic Resonance in anal cancer, functional
Magnetic Resonance in anal cancer, assessment post treat-
ment of anal cancer, Magnetic Resonance after chemo-
therapy in anal cancer, endo sonography after neoadjuvant
therapy in anal cancer. The inclusion criteria were: clinical
study evaluating anal cancer, clinical study evaluating new
functional imaging criteria in the MR study of patients
with anal cancer, and clinical study evaluating follow-up
after chemoradiotherapy of patients with anal cancer.
Articles published in the English language from Janu-
ary 1989 to June 2016 were included. The references
of these articles were also analyzed to identify ori-
ginal studies that were not identified by the search of
the data. Exclusion criteria unavailability of full text
and absence of original research data (editorials, case
reports, etc.).
Results
A Pubmed search yielded 9 articles for key endo sonog-
raphy in anal cancer, 2 articles for key 3 Dimensional-
Endoanal-sonography in anal cancer, 442 articles for key
Magnetic Resonance in anal cancer, 25 articles for key
functional Magnetic Resonance in anal cancer, 31 arti-
cles for key assessment post treatment of anal cancer, 60
articles for key Magnetic Resonance after chemotherapy
in anal cancer, 1 articles for key endo sonography after
neoadjuvant therapy in anal cancer. According to inclu-





3D-EAUS is a valuable tool to evaluate the normal anat-
omy and diseases of the anal canal (Fig. 2). It is easy to
perform and to reproduce, with high diagnostic accur-
acy. It is painless, without patient preparation. It pro-
vides excellent imaging of the rectal and anal wall, of the
internal and external sphincters (Fig. 3), of the inter-
sphincteric plane, and of the position of the anal verge, es-
sential for planning surgical approach. 3D-EAUS is the
first investigation in benign anal diseases [17]. As showed
by Alabiso et al. [17] it is a diagnostic method able to
identify the intersphincteric or submucosal lesion, depict-
ing the intersphincteric plane and both the internal and
external sphincters, whose identification is critical to the
proper patients management [12]: to identify a T1 lesion
allows conservative management with sphincter sparing.
Kolev et al. [18] demonstrated that T category on 3-D
EAUS correlated with histopathology in 92.9 %, and N cat-
egory correlated with histopathology in 81.6 %, so the 3D
EAUS is a valuable diagnostic tool in the assessment of
the anal cancer, even for stage T1 [18]. Christensen et al.
in 2004 compared 3-D EAUS with 2-D EAUS and showed
Fig. 2 3D EAUS: longitudinal plane; external and internal sphincter
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that 3D improved detection of perirectal nodes, becoming
a powerful tool in staging and planning of treatment [19].
Also Kim [20] analyzed the role of EAUS showing that it
can accurately detect the depth of anal cancer into the
sphincters with a focus on tumor penetration. This aspect
is important because the depth of penetration is closely as-
sociated with the prognosis, demonstrating that EAUS may
be superior for the detection of superficial small anal can-
cers compared to MRI and therefore recommended for T
staging. For lymph node staging, Kim showed that EAUS
should be supplemented by MRI, since US has a limited
field of view [20]. In addition, Regadas et al. [21] showed
that 3D EAUS, with high spatial resolution, could be a
valuable tool to diagnose anorectal diseases, adding import-
ant features about the therapeutic decision. Although the
diagnostic performance is similar to that of MRI, 3D EAUS
has the advantages of being easier, quicker, cheaper and
better tolerated by patients than the other. The 3D EAUS
has a role not only in detection and staging, but also as a
guide to treatment. In fact, Christensen et al. [22] showed
that 3D EAUS could lead to brachytherapy in anal carcin-
oma, demonstrating how it could optimize the implant
procedure and offer better information for dose planning.
Post treatment assessment
The advent of new therapies, more and more personal-
ized to the patients and the recent improvements of
neoadjuvant therapies, radiotherapy and chemotherapy
can cause a down staging of the lesion, such as to make op-
erable lesions that were not resectable before treatment
[12–14]. In addition, the choice of low-invasive surgery,
with sphinter saving technique, increases the risk of recur-
rence. Therefore is mandatory identifying effectiveness of
neoadjuvant therapy and of the recurrent disease. In this
context, the role of 3D EAUS is unclear. Christensen et al.
[23] showed that the 3D EAUS was an accurate technique
in detection of recurrence of anal cancer in combination
with anoscopic and digital rectal examination post surgery.
Conversely, Peterson et al. [24] demonstrated that EAUS
did not provide any advantage compared to DRE in identi-
fying local recurrence, and should not be recommended for
routine surveillance. To the best of our knowledge, there
are no scientific evidences of effectiveness of 3D EAUS in
the assessment of anal tumor after neoadjuvant therapy.
3D-EAUS has some limitations since it is highly oper-
ator dependent and it does not allow a reliable distinc-
tion between tumor and fibrosis.
Magnetic resonance imaging
Detection and staging
MRI is the gold standard in oncological pelvic examin-
ation, providing morphological and functional data. MRI
leads to an excellent imaging of the rectal and anal wall,
so to obtain an accurate evaluation of cancer stage in-
cluding tumour infiltration degree, involvement of the
internal and external sphincters, of the intersphincteric
plane, and an effective assessment of lymph nodes status
thanks to improvement of phased array coils and endorec-
tal coils. A standard MRI protocol for anal cancer staging
consists of turbo spin-echo MR sequences T2-weighted in
Fig. 3 3D EAUS: tridimensional reconstruction
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the 3 spatial planes (coronal, transversal and sagittal) with
high spatial resolution (Fig. 4) [25, 26]. Moreover, the high
temporal resolution due to powerful gradients allows perfu-
sion and dynamic studies after contrast media injection, in
order to obtain functional data to assess the type of tissue
blood supply, which may guide patient selection for neoad-
juvant therapies and evaluate the treatment [25, 26]. So that
a dynamic study acquired according to the technique Dy-
namic Contrast Enhanced (DCE) should be performed
(Fig. 5). Moreover, functional parameters can be obtained
by Diffusion Weighted Imaging (DWI). DWI supplies infor-
mation of water mobility. This can be employed to assess
the microstructural organization of a tissue like cell density,
cell membrane integrity and ultimately cell viability [27].
An anal cancer MRI protocol should be also performed
with DWI sequence (Fig. 6).
MRI is a valuable diagnostic tool in anal cancer sta-
ging, although the major limitation is an incorrect detec-
tion of T1 patients [16], neither it would seem that the
use of the endoanal coil could increase the detection rate
[27]. In fact Matsuoka et al. [27] demostrated that
endorectal coil and phased array coil showed similar
diagnostic accuracy in detection of anal cancer. Several
studies evaluated the MRI accuracy compared to EAUS,
in rectal cancer patients staging, and the data suggested
that EAUS provides an excellent visualization of the
layers of the bowel wall conversely to MR so that EAUS
provides better detection of superficial tumor. In evalu-
ation of perianal and perirectal nodes, the techniques are
complementary tool, while MR should be chosen for iliac
and inguinal nodes [28–33]. Also, Burdan et al. [33]
showed that the possibility to obtain functional informa-
tion by MR as the increased signal on DWI and low appar-
ent diffusion coefficient (ADC) values seem to predict the
involvement of pelvic lymphatic nodes better than their
size alone. According to Attenberger et al. [34], ADC
measurements were useful in differentiating N stages.
Mizukami et al. [35] reported a high negative predictive
value ofDWI, while Heijnen et al. [36] showed that DWI in-
creases the detection rate of lymph node, but alone it is not
reliable for differentiating between benign and malignant
nodes. Recently, Seber et al. [37] evaluated the DWI com-
pared with morphological MRI for the differentiation of be-
nign from malignant nodes in different regions of the body.
They concluded that morphological data was better than
DWI data alone or associated to morphological data, how-
ever DWI and ADC might play a role in node
characterization.
Although the most widely used imaging tool for guid-
ance of interstitial radiotherapy in anal cancer brachyther-
apy (BT) is EAUS [22], since it provides a good target
delineation and a very easy administration, however also
MRI is characterized by excellent contrast and spatial reso-
lution, providing information on tumor size, local extent
and spreading, invasion of adjacent organs, and more ac-
curate nodal involvement. Furthermore, due to the use of
perfusion and diffusion data, MRI can also provide infor-
mation concerning functional characteristics and microcir-
culation of the tumor. These features could be useful for
the modulation of the target dose and the improvement of
the treatment results. Tagliaferri et al. [38] evaluated the
role of MRI in anal BT and they showed that although the
use of MRI had some limitations, such as costs and higher
time required, it could be the preferable choice for the
modulation of the target dose according to perfusion and
DWI parameters. In fact, the functional features could
help to deliver a very high dose only to a small volume, in
order to reduce the dose, resulting in lower toxicity and in-
creased local control (Table 3).
Post treatment assessment
MR imaging plays an important role in therapeutic as-
sessment, properly stratify patients into responders or
non responders to neoadjuvant treatment, surveillance
after surgery, and evaluation of suspected disease fall-
out [25, 26]. The possibility to obtained functional data
by DCE-MRI and DWI allows to relive vitality tissue
and to differentiate fibrosis by residual tumour after
anti-angiogenetic treatments [25, 26].
In clinical practice, the recognized criteria for the as-
sessment after therapy are response evaluation criteria in
solid tumor (RECIST), which are based on size criteria.
Fig. 4 TSE T2-W in axial plane; (a) anal cancer infiltrating internal and external sphincter on the left; inguinal node. b post treatment assessment:
partial response with involvement of internal sphincter; inguinal node disappearances
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Although the morphological evaluation on MR images
can identify a patient as responder to therapy, based on
decreased of maximum diameter of the lesion,, it does
not establish if the remaining tissue is cancer or fibrosis,
and it does not seem to be linked to patient outcome.
Goh et al. [39] evaluated the MRI pre- and post- treat-
ment. They showed that early assessment of response by
MRI at 6−8 weeks, based on RECIST criteria, is unhelp-
ful in predicting future clinical outcome.
Several studies evaluated the DCE-MRI as promising
tool to monitor assessment after neoadjuvant therapy
thanks to the link between tumor growth and angiogen-
esis [40, 41]. It is known that angiogenesis is a key factor
in the growth of cancer, therefore the characterization of
the angiogenic status of the lesions could allow a more
personalize treatments [13].
Many clinical trials showed that angiogenesis inhib-
ition could increase the treatment effectiveness. Imaging
techniques is able to assess tumour vascularization and
the capability to improve the treatment management in
oncologic patients [40, 41].
DCE-MRI consists of a multiple T1-weigthed images
acquired before and after contrast medium administra-
tion in specific time linked to study temporal resolution.
It measures the rate of contrast movement between the
intravascular and extra-cellular extravascular space. This
rate reflects tissue microvasculature permeability and perfu-
sion. In order to assess tissue perfusion by means of DCE-
MRI, several approaches to analyse Time Intensity Curve
(TIC) were proposed in literature. The most commonly
used in the radiological practise is the visual inspection of
TIC [25]. According to Petrillo et al. [26] the TIC visual in-
spection to assess neoadjuvant response in rectal cancer
patients, has a sensitivity, a specificity and an accuracy re-
spectively of 94 %, 76 % and 84 % in complete responders.
Also quantitative and semi-quantitative analysis performed
Fig. 5 Same patient of 4: post contrast sequences; in (a) pre treatment: contrast enhancement of anal cancer infiltrating internal and external
sphincter on the left. In (b) post treatment assessment: the lesion shows a lower contrast enhancement
Fig. 6 Same patient of 4 and 5: DWI sequences. In (a) b800 pre-treatment examination: cancer shows hyperintese signal, in (b, a, d, c): the lesion
appear hypointhense. In (c) post treatment b800, a lower signal than in A with a higher signal in (a, d, c) than in b
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to evaluate vascular assessment tissues. Petrillo et al. [25]
performed a semi-quantitative analysis and individuated a
combination of 2 TIC descriptors, ΔMSD (relative change
of maximum signal difference) and ΔWOS (relative change
of wash-out slope), named Standardized Index of Shape
(SIS) [25]. This combination reached a sensitivity of 93.5 %
and a specificity of 82.1 %. Moreover, SIS improved nega-
tive predictive value to 88.5 % and positive predictive value
to 89.6 %. Jones et al. [42] performed multiparametric MRI,
including morphological, DWI and DCE sequences, to de-
termine whether the early changes in multiparametric
parameters, especially ADC and quantitative parameters,
Ktrans and Kep, during neoadjuvant therapy can predict
for later response in anal. However, according to Torkzad
et al. [43] the real role of DWI and DCE MRI in post treat-
ment assessment remains to be established, requiring a
greater number of scientific studies.
Conclusion
Although the anal caner is rare neoplasm, the incidence of
the tumor shows an incremental trend that reflects an in-
crease in infection rates of HPV and HIV and immuno-
suppression state. The real rule of imaging techniques in
detection, staging and follow-up of tumor is unclear. 3D
EAUS and MRI are the best diagnostic tools in detection
of the lesion, although 3D EAUS is more accurate than
MRI for T1 stage (Table 4). However, the MRI allows to
properly detect neoplastic nodes both to higher field of
view and functional data. The MRI is the techniques of
choice in post neoadjuvant treatment to properly stratify
patients into responders or non responders.
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